CD274 and carcinoid tumor: Of that, 21% of the well-differentiated pNETs and 25% of the moderately differentiated pNETs were PD-L1-positive tumors, being PD-L1+ carcinoid tumors, and 16 being PD-L1+ pNETs receiving treatment.